Trials / Recruiting
RecruitingNCT07213791
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 241 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
Conditions
- Ovarian Neoplasms
- Breast Neoplasms
- Pancreatic Intraductal Neoplasms
- Colorectal Neoplasms
- Esophageal Neoplasms
- Stomach Neoplasms
- Cholangiocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY4337713 | Administered IV. |
Timeline
- Start date
- 2025-10-22
- Primary completion
- 2028-07-01
- Completion
- 2033-03-01
- First posted
- 2025-10-09
- Last updated
- 2026-04-17
Locations
28 sites across 4 countries: United States, Germany, Japan, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07213791. Inclusion in this directory is not an endorsement.